REZOLUTE INC (RZLT) Stock Fundamental Analysis

NASDAQ:RZLT • US76200L3096

3.21 USD
-0.08 (-2.43%)
At close: Feb 27, 2026
3.23 USD
+0.02 (+0.62%)
After Hours: 2/27/2026, 8:00:02 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to RZLT. RZLT was compared to 520 industry peers in the Biotechnology industry. While RZLT has a great health rating, there are worries on its profitability. RZLT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • RZLT had negative earnings in the past year.
  • In the past year RZLT has reported a negative cash flow from operations.
  • RZLT had negative earnings in each of the past 5 years.
  • In the past 5 years RZLT always reported negative operating cash flow.
RZLT Yearly Net Income VS EBIT VS OCF VS FCFRZLT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M

1.2 Ratios

  • RZLT has a Return On Assets of -60.76%. This is comparable to the rest of the industry: RZLT outperforms 42.34% of its industry peers.
  • RZLT has a Return On Equity of -65.80%. This is comparable to the rest of the industry: RZLT outperforms 57.47% of its industry peers.
Industry RankSector Rank
ROA -60.76%
ROE -65.8%
ROIC N/A
ROA(3y)-45.28%
ROA(5y)-42.37%
ROE(3y)-49.01%
ROE(5y)-50.92%
ROIC(3y)N/A
ROIC(5y)N/A
RZLT Yearly ROA, ROE, ROICRZLT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2K 4K 6K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for RZLT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RZLT Yearly Profit, Operating, Gross MarginsRZLT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

8

2. Health

2.1 Basic Checks

  • The number of shares outstanding for RZLT has been increased compared to 1 year ago.
  • Compared to 5 years ago, RZLT has more shares outstanding
  • There is no outstanding debt for RZLT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RZLT Yearly Shares OutstandingRZLT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
RZLT Yearly Total Debt VS Total AssetsRZLT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

2.2 Solvency

  • An Altman-Z score of 11.25 indicates that RZLT is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 11.25, RZLT belongs to the best of the industry, outperforming 82.95% of the companies in the same industry.
  • RZLT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 11.25
ROIC/WACCN/A
WACCN/A
RZLT Yearly LT Debt VS Equity VS FCFRZLT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 14.18 indicates that RZLT has no problem at all paying its short term obligations.
  • RZLT has a Current ratio of 14.18. This is amongst the best in the industry. RZLT outperforms 90.42% of its industry peers.
  • A Quick Ratio of 14.18 indicates that RZLT has no problem at all paying its short term obligations.
  • RZLT has a better Quick ratio (14.18) than 90.42% of its industry peers.
Industry RankSector Rank
Current Ratio 14.18
Quick Ratio 14.18
RZLT Yearly Current Assets VS Current LiabilitesRZLT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 23.77% over the past year.
EPS 1Y (TTM)23.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, RZLT will show a very strong growth in Earnings Per Share. The EPS will grow by 26.81% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y26.39%
EPS Next 2Y13.68%
EPS Next 3Y18.24%
EPS Next 5Y26.81%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RZLT Yearly Revenue VS EstimatesRZLT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M 500M
RZLT Yearly EPS VS EstimatesRZLT Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -5 -10 -15

0

4. Valuation

4.1 Price/Earnings Ratio

  • RZLT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year RZLT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RZLT Price Earnings VS Forward Price EarningsRZLT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RZLT Per share dataRZLT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

  • RZLT's earnings are expected to grow with 18.24% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.68%
EPS Next 3Y18.24%

0

5. Dividend

5.1 Amount

  • RZLT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

REZOLUTE INC

NASDAQ:RZLT (2/27/2026, 8:00:02 PM)

After market: 3.23 +0.02 (+0.62%)

3.21

-0.08 (-2.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-12
Earnings (Next)05-11
Inst Owners109.4%
Inst Owner Change0.68%
Ins Owners1.52%
Ins Owner Change0.78%
Market Cap297.66M
Revenue(TTM)N/A
Net Income(TTM)-84.23M
Analysts80
Price Target6.63 (106.54%)
Short Float %22.9%
Short Ratio2.24
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.03%
Min EPS beat(2)-15.34%
Max EPS beat(2)33.41%
EPS beat(4)1
Avg EPS beat(4)-4.03%
Min EPS beat(4)-18.3%
Max EPS beat(4)33.41%
EPS beat(8)3
Avg EPS beat(8)-1.42%
EPS beat(12)7
Avg EPS beat(12)3.11%
EPS beat(16)11
Avg EPS beat(16)9.26%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4%
PT rev (3m)-57.3%
EPS NQ rev (1m)-2.81%
EPS NQ rev (3m)26.06%
EPS NY rev (1m)0%
EPS NY rev (3m)37.06%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.33
P/tB 2.33
EV/EBITDA N/A
EPS(TTM)-0.93
EYN/A
EPS(NY)-0.69
Fwd EYN/A
FCF(TTM)-0.83
FCFYN/A
OCF(TTM)-0.83
OCFYN/A
SpS0
BVpS1.38
TBVpS1.38
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -60.76%
ROE -65.8%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-45.28%
ROA(5y)-42.37%
ROE(3y)-49.01%
ROE(5y)-50.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.18
Quick Ratio 14.18
Altman-Z 11.25
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y26.39%
EPS Next 2Y13.68%
EPS Next 3Y18.24%
EPS Next 5Y26.81%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-23.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-44.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-44.95%
OCF growth 3YN/A
OCF growth 5YN/A

REZOLUTE INC / RZLT FAQ

What is the fundamental rating for RZLT stock?

ChartMill assigns a fundamental rating of 3 / 10 to RZLT.


Can you provide the valuation status for REZOLUTE INC?

ChartMill assigns a valuation rating of 0 / 10 to REZOLUTE INC (RZLT). This can be considered as Overvalued.


What is the profitability of RZLT stock?

REZOLUTE INC (RZLT) has a profitability rating of 1 / 10.


What is the earnings growth outlook for REZOLUTE INC?

The Earnings per Share (EPS) of REZOLUTE INC (RZLT) is expected to grow by 26.39% in the next year.


Can you provide the dividend sustainability for RZLT stock?

The dividend rating of REZOLUTE INC (RZLT) is 0 / 10 and the dividend payout ratio is 0%.